Bruce the Stock Guy, Can you check with IHUB if they can take down the Yellow sticky post #1326 "Beware Bumpers" by Calsurfer.
It is at the top of the page. Filled with nonsense.

Blackcat7717

For those of you that are looking to buy a large position.
9 ot of 10 times VFIN & UBSS has them. Happy Hunting!

Blackcat7717

AMEN!!!!

Blackcat7717

The ITL group of Investors are in Love with Dr. Harnoy
and not so much with Seth Shaw. Almost like Obama & Bush. LOL

Blackcat7717

Gottagetthat, Have you not heard the phrase Buy low & Sell High.

I find this fact fascinating. Those who invested in both ITL & TAUG believe that ITL will be a BIG success. They never mention that they are thinking of buying more shares of TAUG at this very low price. Maybe someone who owns both can shed some light on this matter. Why are they not interested in buying more TAUG?

If they own TAUG at a higher price why are they not considering averageing down and buying more. If TAUG made them a profit in the short term, this Gain would reduce their overall cost in ITL.

Here is the difference I see between the between the two companies:

One is regulated by the SEC the other is not.
One has liquidity the other does not.
One has diversification of product the other does not.

Also, if someone invested in TAUG, why would they BASH it and praise ITL? The trials for ITL will take 2 1/2 years for results. With any great news from Bangkok TAUG will be trading at a much higher price per share.

Blackcat7717

Oceanslow1 This is the only way I can respond to what you say. If I you had 2 children to raise would you treat them the same or would you treat them differently.

Child 1 Graduated Harvard with honors and is running the Family business.This child surpassed my expectation and would make me very happy.

Child 2 Decided to start his career from scratch after graduating High School. This was not my wish, however I love both and support both. I do not tell him he should be like his brother. I gave him all my support. He started his own business. After several years he sold out to a company listed on the NYSE for $15 Million Dollars. Child 1 is working for a law firm.

If you still own stock in TAUG you must change your ways and support Seth Shaw. How can you guess what Seth will accomplish
with the company you claim you still own.

You must apology to Seth Shaw and support both individuals.

Blackcat7717

THE GOOGLES5 I am happy to see NEW board members contribute info to IHUB. All of you must wonder why the stock is trading so low at $.05. Many investors had invested heavy in TAUG & ITL. TAUG was to merge with ITL and own 25% of the company after the merger. ITL withdrew from this agreement. The $3.5 Million dollars raised for ITL at that time converted into 9% ownership of ITL a Private Co.

Those investors that are negative on TAUG must have sold out at a LOSS, or are still selling out at losses. They must be using their money to invest in ITL direct to average down their cost on ITL at a lower price. ITL sold stock at a $4.00 High when TAUG was trading at $.25. Seth Shaw was able to buy ITL stock at approx. $1.10 a share when TAUG was trading at $.05. TAUG owns 3.3 Million shares of ITL at a cost of $3.5 Million dollars. If Dr. Harnoy makes an announcement on June 2,2013 meeting that ITL will begin the trials in Bangkok in the next few weeks, TAUG investment in ITL will at least triple short term. Target price for TAUG $.15. Long term target $1.00.

Those ITL investors have a HUGE desire for TAUG to fail. This will not happen with Seth Shaw as CEO. I can claim that I have some experience with low price stocks. I have been investing for over 50 years in the OTC market. It is my opinion that Seth Shaw is the most Honest and hard working CEO I have every followed.

My target price does not take into account all the Fantastic progress Seth Shaw has had in the last 6 months.

To the MOOOOOOOOOONNNNN.
Blackcat7717

Bruce the Stock Guy, Many of the Form 4 filings with the SEC are stock purchases in the open market from Officers & directors of TAUG. It is not FREE stock issued to the Officers & directors. Most purchases were done by SETH SHAW. He bought on the open market as high as $.27 cents and as low as $.06.

TAUG owns a 9% stake in ITL. ITL had annual meeting in Israel at the end of May. ITL will have a meeting on JUNE 2, 2013 in Carlsbad Calif. At this time, we do not know when Dr. Harnoy will begin trials in Bangkok. This meeting in Carlsbad might shed some light on the trials.

Blackcat7717

YOU CAN ONLY DISCUSS THE FUTURE. NOTHING FROM THE PAST.

BLACKCAT

That sounds Democratic. The largest investor in the company
will not be discussed. I am sure that will play well for any potential investors on Wall St. OMG.

If anyone is thinking of investing in TAUG or ITL they will both
be listed on the Russian Stock exchange soon. Just my opinion.

Some day I hope the divorce will be over and mature adults can talk calmly about how we will raise the kids.

Blackcat7717

Cal I will hand out crying towels at the end of the day when the market closes at 4:00 PM. I am going on June 2, 2013 not May 19, 2013.

Blackcat7717

Not a Peep from Dr Harnoy either! Why was the conference call cancelled from ITL. Conference calls are done by companies everyday? What happened at the annual meeting? Why didn't you ask that question? Remember we own 9% of ITL! We are not allowed to talk about Dr. Harnoy's past or criticize him in any way, but we are allowed to interrogate and criticize Seth Shaw. The shareholders of TAUG raised $3.7 million dollars for ITL. The shareholders would like to know what happened to it.

This sounds like Obama blaming Bush for everything.

Blackcat7717

I WILL BE ATTENDING FOR SURE.
BLACKCAT

Oceanlow1, It was not by accident and you know it. You could of invested $3.7 Million in ITL and did not. Why did you not? You are a jealous man, Seth has 3.3 Million shares and you do not any amount near that. TAUG (IMUN)had full intentions of raising an additional $6.3 million dollars for Dr. Harnoy to have a 25% stake in ITL. Instead They will raise money to partner with other companies. This choice was Dr. Harnoy, Maybe this was Dr. Harnoy plan from the beginning. Maybe Dr. Harnoy had some big investors
in his pocket right know and that is why he cancelled the deal with (IMUN).(Who knows for sure). Are you a betting man. I bet you TAUG goes to $.25 before ITL goes to $4.00. Motion Granted.

Blackcat7717

On May 19, 2013 the Annual Meeting for ITL will take place.
On June 2, 2013 ITL will have a meeting in Calif. Seth Shaw is
building TAUG back to were it was, and has done a great job in a short period of time. By June or July all of us will be very happy. Think Positive.

Blackcat7717

Oceanlow1 posted this 5 days ago. I rest my case.
This is in his words! Check out post # 1174.

Do not underestimate the importance of Mr. Shaw's work in helping Tauriga achieve this fine status. He held the company together during very difficult times. He offered a steady and honest hand. He will continue to do so to protect our investment.

Go Tauriga!

Blackcat7717

You guys are nuts. We own 9% of a Billion Dollar Company. You
want to spend time on an Independent Article that you do not agree with. Just owning 9% of ITL will put this stock at $1.00 OMG. I guess Seth Shaw had nothing to do with getting the 9% for the Shareholder of TAUG, in your opinion.

Blackcat7717

Calsurfer, It is sad you post information you know nothing about.
If you read any of the legal documents that were filed with the lawsuit you would have the answers to many of your questions. However it is easier to be lazy and not do your DD. In reference to my posting the Biomed Report when it came out. I received
that info from a Google Watch that Marketwire put out. Do you own shares in TAUG? We were on the brink of going out of business. We now are a Holding Company with other business partners. Lets not forget about a 9% partnership with ITL. If you think something is not right here your decision will be simple. Go find a company you can be happy with. Try Apple or Microsoft. Better still call ITL I think that is a GREAT COMPANY.

Blackcat7717

SUBJECT: BIOMED REPORT ARTICLE

After several calls I finally connected with Seth Shaw about the Biomed Report Article and its important that everyone understand that this article was 100 per cent INDEPENDENT. Seth had absolutely no input on the content of that article, only was interviewed for quotes NOT content. Furthermore Tauriga Sciences did not publish that article, the publishing sources was the Independent biotech coverage firm Biomed Reports. If you look at the bottom of the article, it states DISCLOSURES: NONE. That means that these were not promotional materials from the Company, rather a completely independent article from an independent writer who used old press releases and public information to complete the article.

Look at the 2nd to last paragraph, where the article states that Tauriga Sciences has to raise money and faces additional dilution. Seth pointed out to me that, if he had any control over content, that would have been the last thing that he would've included. Broadcasting to the public that you need to raise money, is clearly not what a promotional piece would include.

In my opinion Seth is also unhappy with the references about Har Noy's personal past and the litigation. I can assure you that Seth is looking forward to the future and very much wants ITL to be successful so that the 9% owned by Tauriga is worth money. I have always found Seth to have a high level of integrity and I believe him that this article was independent and that he had no control over the content whatsoever.
Blackcat7717

ITL Shareholder Letter for 2012
Dear Fellow Shareholders,
(TAUG IS A 9% Shareholder in ITL.) 5/10/2013

Immunovative Therapies, Ltd. (“ITL”), has made considerable progress in 2012 toward meeting our goal of eventually defeating the evil that is metastatic cancer. At the beginning of 2012, we set the following goals: (1) obtain regulatory approval to launch a pivotal Phase II/III study of our lead drug candidate, AlloStimTM; (2) obtain regulatory approval for a Phase I/II clinical trial of our AlloVaxTM individualized cancer vaccine product; and (3) expand our patent portfolio protection for possible use in licensing. We are pleased to inform that all these value-added milestones have been successfully accomplished. Thanks to the coordinated efforts of our California and Thailand teams, supported by our manufacturing and operations teams in Jerusalem, we were able to obtain approvals from the Thailand Ministry of Public Health (MOPH) and their Central Ethics Committee for both the Phase II/III AlloStimTM pivotal trial (approval obtained September 2012) for patients with heavily pre-treated metastatic breast cancer and the AlloVaxTM Phase I/II clinical trial (approval obtained January 2013) for patients with recurrent head and neck cancer. These approvals came after extensive regulatory review of our pre-clinical, clinical, and manufacturing data. The Thailand MOPH also reviewed data from patients treated in Thailand under a compassionate treatment program. The compassionate program provided Thai authorities and the clinical investigators with personal experience with the anti-tumor immune properties of our drug and what so far appears to be a realitively benign toxicity profile. Regulatory approval of a pivotal trial is the most significant milestone in our history. Our California and Bangkok teams are now working to put in place the quality assurance and monitoring procedures necessary to assure the safety and stability of the drug after formulation and delivery to the clinical site, the integrity of the clinical data, and compliance with international standards for Good Clinical Practices (GCP). GCP compliance is a requirement for the clinical data to be used in an application to US FDA for marketing approval (see 21 CFR 312.120). Our clinical operations will be monitored by an independent clinical monitor who will report to US FDA monthly and by a Data Safety Monitoring Board
Malcha Technology Park –Bldg 1, Floor 1- Jerusalem 96951 Page 2
(DSMB) of independent medical professionals, including a professional statistician, that will review safety data from our clinical trials. The design of the Phase II/III pivotal study was developed after receiving input and suggestions from US FDA. The study is a double-blind, placebo-controlled, randomized design with a primary end-point of overall survival. The study will recruit 260 patients (130 in each arm). The size of the trial has been statistically powered to detect a difference of 50% or greater in overall survival between the treatment and placebo control arms. If successfully executed and the overall survival end-point reaches statistical significance, we expect that the clinical data from this trial can be used to support marketing applications for AlloStimTM in the USA, as well as in EU and other jurisdictions. The clinical trial will be conducted at the National Cancer Institute (NCI) of Thailand located in Bangkok and the Principal Investigator will be Wirote Lausoontornsiri, MD, a US and Thai dual licensed and trained physician, US Board certified in Hematology/Oncology, and Head of the Clinical Trials and Academic Research Unit at the NCI-Thailand. Accordingly, we believe that we are now only one clinical study away from be able to submit a BLA marketing application to the US FDA under fast track review. Meeting this milestone has the potential to create significant market value for our shareholders, while potentially making a non-toxic and effective alternative to chemotherapy available to patients suffering from late effects of metastatic cancer. We plan it will take 2 years after launch to complete the pivotal study and another 6 months for the data to mature and potentially reach statistical significance. In order to support Phase II/III clinical operations and the increased demand expected for our products in clinical trials, we invested in upgrades to our state-of-the-art cell manufacturing facility and our GMP (good manufacturing practice) operations in 2012. The upgrades have been completed, new quality control procedures have been incorporated and validated, and an updated Chemistry, Manufacturing and Control (CMC) amendment to our IND was submitted to US FDA detailing all the improvements. The upgraded facility includes two class 10,000 clean room facilities, each which contains a class 100 clean operation area (one clean room for AlloStim™ and one for AlloVax™). The facility has interlocked rooms with increasing levels of pressure and air quality. Separate paths are designed for personnel flow and for materials flow. An airlocked room is available for sterile gowning of workers within the facility. Face recognition security systems protect the facility from unauthorized access. Clean space for inventory and finished product storage, product packaging and shipping is was also installed.
Malcha Technology Park –Bldg 1, Floor 1- Jerusalem 96951 Page 3
The GMP facility and operations successfully passed a mock FDA inspection performed by the Biologics Consulting Group (BCG) in April 2012. BCG has been retained to independently monitor our GMP compliance and report monthly to US FDA. Management continues to be dedicated to invest in facilities, personnel and technology to assure the safety of our products and to continuously improve our quality control and quality assurance measures.
We invested considerable resources this year also in building our intellectual property position as we move closer to marketing, with a goal of broader protections and claims focused on increasing the potential for entering into licensing agreements with marketing partners by indication and territory. We are very grateful for the continuing support and investment in time and resources contributed by our patent counsel, Z. Peter Sawicki, and his colleagues at Westman, Champlin & Kelly in Minneapolis. Through their efforts, we have had another 6 key US patents issue since December 2011, bringing our total to 14 issued patents in US and over 100 patents pending around the world. On October 11, 2012, we announced the issuance of US Patent No. 8,273,377 entitled "METHOD FOR ALLOGENEIC CELL THERAPY," which covered the scientific breakthrough discovery of the "Mirror EffectTM." The Mirror EffectTM stimulates the same powerful anti-tumor immune response of mini-transplant procedures which have been proven capable of killing chemotherapy-resistant solid tumors and blood cancers, at the same time the Mirror EffectTM eliminates the Graft vs. Host Disease (GVHD) toxicity and the need for a matched tissue donor associated with Mini-Transplant procedures. On October 16, 2012, we announced the allowance of composition claims of US Patent Application 12/909,517 entitled: "T-CELL COMPOSITIONS THAT ELICIT A TYPE I CYTOKINE RESPONSE." which protects AlloStimTM as a composition of matter, a coveted kind of patent protection in our industry. Peter Sawicki and his colleague also published an article entitled: “Cancer Therapy based on a Mechanism of Action for Controlling the Immune System” which described our patent portfolio in a peer-reviewed journal entitled: “Recent Patents in Endocrinology, Metabolism and Immune Drug Discovery”. (citation: 2013 Jan;7(1):1-10). In this article, our patent portfolio was described as being capable of protecting not just a product, but was described as being capable of creating a whole new industry. It was stated that our patent portfolio could represent for immunotherapy the same significance as the landmark “one-click” patent that served to create the internet marketing industry. Our focus for 2013 is now to obtain sufficient financing to launch and complete our approved clinical studies. Since our incorporation in May 2004, your management has been able to meet and overcome significant challenges in order to reach our current advanced stage of development. Despite being chronically undercapitalized and understaffed (averaging only 3-6 months of cash available for almost our entire development cycle), we have managed to overcome many significant obstacles by making good decisions and spending our limited funds wisely. To come within a single clinical trial of FDA marketing approval of a new class of drug therapy is an amazing accomplishment for a small biotech company, a milestone
Malcha Technology Park –Bldg 1, Floor 1- Jerusalem 96951 Page 4
rarely reached even by biopharmaceutical companies with large financial backing and/or in partnership with a major pharmaceutical company. Significantly, we have been able to accomplish this milestone without excessive dilution to our shareholders. Our success to date has been due to the creativity, commitment, motivation and skill of our worldwide team of employees, consultants and collaborators. This team is our major asset and, together with our shareholder’s willingness to financially support us, creates a powerful partnership that has enabled us to move closer to realizing our mission to defeat the evil that is metastatic cancer. Our team has expanded in 2012, please join me in welcoming the newest members to the Immunovative family. We are proud that our technology and work culture is able to attract such high quality, dedicated and hard-working individuals:
Dr. Irit Yaniv, MD, MBA Member (elect), Board of Directors
Evan Fishman, CPA Chief Financial Officer
Dr. Zivile Katiliene, PhD Director, Regulatory Affairs and Clinical Operations
Mordehai Koskas Manager of Quality Assurance
Tomer Zerbib Clean room and QC technician
Nadia Sinai Clean room and QC technician
Siraprapa Khampechdee Office Manager—Thailand
Dr. Wirote Lausoontornsiri, MD Hematologist/Oncologist and Principal Investigator
Dr. Somjin Chindavijak, MD Surgeon and Principal Investigator
We have now reached a critical point in our development and our future depends upon our ability to close on a significant financing and/or strategic partnership within the next few months. We were hit with a significant setback when we did not receive the funding we expected under our contract with NovoEnergies, formerly Immunovative, Inc. and now Tauriga Sciences (hereafter “IMUN”). This forced your Board to cancel the exclusive licensing agreement with IMUN. IMUN subsequently filed a lawsuit against us. In settlement of the lawsuit, which included mutual consent to termination of the license agreement, we agreed to issue 3,280,000 non-voting shares to IMUN in exchange for the $3,469,000 that was actually transferred. The shares issued to IMUN is equal to 9% of our outstanding shares. IMUN has since changed its name and trading symbol and is no longer associated with us, or our technology, except as a shareholder. We wish to welcome the public holders of IMUN stock (now OTCQB:TAUG) to the Immunovative Shareholder family. We also are grateful to our attorneys, Mitchell Shelowitz and Doron Latzer and colleagues at Pearl Cohen Zedek Latzer, that represented us expertly in this litigation which enabled a quick, favorable and cost effective resolution to the dispute.
Malcha Technology Park –Bldg 1, Floor 1- Jerusalem 96951 Page 5
Your management is now in negotiations with several potential funding sources, including venture capital, corporate strategic partners, private and public investors. We are also considering several options for near term revenue generation. As often happens in difficult situations, there are also opportunities that are created. One of the options we are currently contemplating may provide existing shareholders with an opportunity to support our continued advancement by being provided additional investment opportunity under special favorable terms. We will be providing shareholders with information regarding our financing plans as they materialize in future communications. Immunovative is a rapidly growing biopharmaceutical company with ambitious goals. We aim to create shareholder value by following a clear and convincing strategy for meeting well defined value-added milestones. The progress we have made in 2012 is a clear indication that we continue to be executing exceptionally on this strategy. Currently, access to capital is the milestone we must achieve and the major theme underlying our ability to continue to execute on our strategic plans. We look forward with enthusiasm to the challenges ahead in attempting to obtain the financing needed to advance to the pivotal trial stage of our product development cycle. We are grateful for the trust and support of our shareholders in supporting our efforts. Your management looks forward to visiting with you and answering your questions at our Annual Shareholder’s meeting to be held May 19, 2013 at 12:00 at the offices of our attorneys Pearl Cohen Zedek Latzer in Herzliya Petuach. Information on the meeting agenda and issues up for shareholder vote will be sent separately. We also plan to conduct an informational meeting for US shareholders in San Diego, California on Sunday, June 2, 2013. Information on the place and time will also be sent in a separate communication. Respectfully Submitted on behalf of your Board of Directors,
Dr. Michael Har-Noy May 8, 2013. Chief Executive Officer
Email: harnoy@immunovative.co.ilMay 8, 2013
Blackcat7717

Badman I read the company SEC filings over again. The date the new accountant begain working for SCRH is Jan 14, 2013.I hope the financials will get caught up no later than June 2013.With Atlantic City opening on July 4, 2013 we should be on our way.

Blackcat7717

ITL ANNUAL MEETING: 05/19/2013 AT 12:00 ISRAEL

May 8, 2013

To: The Shareholders of Immunovative Therapies Ltd.

Dear Shareholder:

Re: Invitation to Annual and Special Meeting of the Shareholders of Immunovative Therapies Ltd.
You are hereby invited to an Annual and Special Meeting of the shareholders of Immunovative Therapies Ltd. (the "Company") that will be held at the offices of Pearl Cohen Zedek Latzer in 5 Shenkar St. Herzlia, Israel, on May 19th, 2013, at 12:00 Israel Time (the "Meeting").
On the Agenda of the Meeting:
1. Presentation of the Company's Annual Financial Statements, and Discussion. Review of the Company’s audited financial statements for the fiscal year ended on December 31, 2011 attached hereto as Exhibit A.
2. Appointment of Independent Auditors. Ratification of the appointment of Ernst & Young to serve as independent auditors of the Company for the fiscal of 2012 that has ended on December 31, 2012, and appointment of Ernst & Young to serve as independent auditors of the Company for the fiscal of 2013 that will end on December 31, 2013 and authorization of the Board of Directors to affix their compensation.
3. Appointing Board Members.
3.1. Approval and ratification of the appointment of Dr. Irit Yaniv, MD to serve as a Board member of the Company, having such rights and obligations as forth in the Articles of Association of the Company as amended from time to time, with such an appointment to be in effect as of May 19, 2013, and to be granted with 330,000 Options to purchase Ordinary Shares of the Company, under the Imunovative's 2006 Share Option Plan. Dr. Yaniv’s curriculum vitae is attached as Exhibit B. Dr. Yaniv will join current Board members, Dr. Michael Har-Noy and Steve Rhodes.
3.2. Approval and ratification of the appointment of Dr. Irit Yaniv, MD as a consultant to the Company, providing consulting services for a consulting fee of NIS 3,000 plus VAT monthly, to be in effect as of December 2012.
4. Amendment of the Articles of Association of the Company. Approval of the amendment to the Articles of Association of the Company as follows (the "Restated Articles"):
4.1. To add the following language as the new Section 43 to the Restated Articles: "43. Number. The Board shall consist of no less than one (1) and no more than seven (7) members. In the event that the Board consists of less than seven (7) members, the Board may appoint additional members to the Board. The membership of members so appointed shall remain in effect until the first Annual General Meeting following their appointment".
2
5. Granting an Exemption and Indemnity letter to the Company's the Office Holders. To approve the grant of an Exemption and Indemnification Letter, in substantially the form attached hereto as Exhibit C, to be issued to the Company's current and future Officers and Directors, pursuant to which the Company shall undertake to exempt and indemnify such Officers and Directors from monetary liabilities to the fullest extent permitted by law, as set forth in the Indemnification and Exemption Letter.
All shareholders are cordially invited to attend the Meeting in person. Shareholders who are unable to attend the Meeting, whether in person, by phone or in any other manner deemed acceptable for attending a shareholder's meeting under the Company's Articles of Association, may either appoint a proxy representative, or provide the Company with a duly filled and signed the proxy form attached hereto as Schedule 1.
The Board encourages shareholders to sign a General Proxy which provides Dr. Har-Noy, founder, Director and CEO with the right permanent proxy to vote all your shares, including in any written consent of the shareholders of the Company. This General Proxy will assist the Company when negotiating the terms of any future financing with institutional investors, Should you agree to provide Dr. Har-Noy with your General Proxy, please send to the Company a duly filled and signed proxy in the form attached hereto as Schedule 2.
All proxies should be sent to the attention of Mr. Evan Fishman: (i) by registered mail to the Company's offices at Malcha Technology Park, Building No. 1, First Floor, Jerusalem, 96951 ISRAEL or (ii) by facsimile number: +972-2-6505088.
Mr. Evan Fishman shall be happy to assist with any questions, you can contact him at +972-2-6506288 or at evan@immunovative.co.il Please note that the information contained in this invitation and all schedules thereto is to be kept in strict confidentiality and is intended only for the shareholders of the Company.
All shareholders of the Company are hereby requested to update their contact information which includes address, e-mail, telephone and facsimile numbers, and deliver such information to the Company by facsimile number: +972-2-6506288 or e-mail evan@Immunovative.co.il.
Sincerely Yours,
Dr. Michael Har Noy, Director
Immunovative Therapies Ltd.
3
Schedule 1
Proxy for the Meeting
To:
Immunovative Therapies Ltd.
Malcha Technology Park
Building No. 1, First Floor
Jerusalem, 96951
Israel
Further to that certain Invitation to the Annual Meeting of the Shareholders of Immunovative Therapies Ltd. (the "Company") to be held at the offices of Pear Cohen Zedek Latzer, 5 Shenkar St. Herzlia, Israel, on May 19th, 2013, at 12:00 Israel Time (the "Meeting" and the "Notice"), the undersigned Shareholder hereby appoints Dr. Michael Har-Noy, or any other person designated by the Company, with full power of substitution, the true and lawful attorney, agent and proxy of the undersigned, to vote as specified below, with respect of all of the shares of the Company which the undersigned is entitled in any capacity to vote (the "Shares"), at the Meeting.
The Shares will be voted or withheld from voting on any ballot that may be called for, in the manner directed herein by the undersigned shareholder. If a choice is specified with respect to any matter to be acted upon, the Shares shall be voted or withheld from voting accordingly. In the event that this Proxy is not delivered to the Company the Shares held by you shall not be considered present in the Meeting, and will not be taken into account for as Shares participating in the Meeting. Where no vote is cast in respect to any matter to be acted upon, the Shares represented hereby shall, on any ballot that may be called for, be voted as abstaining Shares in regards to such matters.
The undersigned represents that he, she or it is the registered owner of and has the right and legal power to execute this Proxy with respect to the number of issued and outstanding shares of the Company held by him, her or it.
By signing herein below, the undersigned waives the right to receive an advance notice of seven (7) days prior to the date of the Meeting. In the event that all shareholders sign the Proxy forms, the Meeting shall not be held at the date mentioned above and the signed Proxies shall be deemed to establish a unanimous written consent of the shareholders of the Company.
Matter to be Resolved
For
Against
Abstain
Appointment of Ernst & Young as independent auditors and authorization to the Board of Directors to affix their compensation.
?
?
?
Approval and ratification of the appointment of Dr. Irit Yaniv.
?
?
?
Approval of the amendment to the Articles of Association of the Company to include the proposed language.
?
?
?
Approval of the grant of an Exemption and Indemnification Letter.
?
?
?
________________________________

Blackcat7717

Hello Badman, They took SCRH to the woodshed today. I am at a loss
as to why. The Club in Atantic City will open in the Taj Mahal
on the 4th of July 2013. This will boost SCRH revenues greatly.

Blackcat7717

Oceanslow1 What is the date of the Shareholders meeting.

Blackcat7717

Oceanslow1 Governance is an important issue. Transparency is just as important. Either that or inform shareholders how to find out this information. Now if we can just get this from Dr. Harnoy.

Blackcat7717

Investors here is some good reading.

http://www.marketwire.com/press-release/tauriga-sciences-ceo-pulls-off-impressive-turnaround-more-to-come-otcqb-taug-1787482.htm

Blackcat7717

The only possibility is that some old shareholders in TAUG want to help Dr. Harnoy to raise money to start the trials in Bangkok are selling TAUG to buy ITL (a Private Company). After this seller is done we will see higher prices soon. Either way TAUG owns a 9% position in ITL.

Blackcat7717

Starbuxsux: That Bid is not 37 million to buy. It is 3.72 Million
to buy at $.10. Also under that bid is 5 Million to buy at $.099
you cannot see the second bid because NITE has both orders.

Fasten your seat belt.

Blackcat7717

Thank you MHB. Now that TAUG is a 9% Shareholder in ITL it will be important to follow all the events taking place with ITL. TAUG paid $3.6 million dollars for 3.3 Million Shares at a cost of $1.10 per share. Since the time we have been investors in IMMU/TAUG the range of ITL has been a High of $4.00 and a Low of $1.10. Any news with the FDA or the starting of the Trials in Bangkok will increase the value of TAUG ownership.

Remember this just a bonus for us. Seth Shaw will be doing
a great deal of Fantastic deals in the future.

Blackcat7717

PRESS RELEASE:THIS APPOINTMENT WILL BE FANTASTIC FOR ALL OF US.

Tauriga Sciences, Inc. Appoints Stella M. Sung, Ph.D. to Position of Chief Operating Officer Effective Immediately

LOS ANGELES, CA -- (Marketwired) -- 04/15/13 -- Tauriga Sciences, Inc. (OTCQB: TAUG) or ("The Company" or "Tauriga") has today announced the appointment of Stella M. Sung, Ph.D. ("Dr. Sung") to the position of Chief Operating Officer ("COO") effectively immediately. In assuming this position, Dr. Sung will oversee the evaluation process and structuring of potential biotech transactions, including: due diligence, valuations, DCF modeling, and capital requirements.

Tauriga CEO Seth M. Shaw commented, "The addition of Dr. Stella Sung to the Company's core management team as Chief Operating Officer is a major achievement for the Company. Her outstanding rolodex of institutional investors and access to intriguing opportunities in the life sciences space are of great importance to the Company moving forward."

Newly appointed Tauriga Chief Operating Officer, Dr. Stella Sung stated, "I am enthusiastic about building Tauriga's portfolio of diversified assets in the health care space. Serving as the Company's COO enables me to source and structure transactions with the goal of maximizing shareholder value, and Tauriga is already creating a pipeline of potential deals."

Please see below Bio for Dr. Stella M. Sung, Chief Operating Officer -- Tauriga Sciences, Inc.:

Dr. Stella M. Sung brings almost 20 years of leadership experience in the healthcare sector as both a senior operating executive and an early stage life science venture capitalist. Dr. Sung is currently Business Development Officer of Avita Medical, a public regenerative medicine company, and Managing Director of Pearl Street Venture Fund, a life science venture fund. She previously held the position of Chief Business Officer of Cylene Pharmaceuticals, a venture-backed oncology company. Dr. Sung has served as a Managing Director or General Partner for several life science venture firms, including Coastview Capital (founded by former Amgen CEO Gordon Binder) and Oxford Bioscience Partners. She has led venture rounds of financing for seven transactions, co-founded two biotechnology companies, served on 7 Boards of Directors and served as Chairman of the Board for four biotechnology companies. Previously, she focused on life science and health care investments at Advent International, a global private equity firm that has raised over $6 billion in cumulative capital to date. Dr. Sung received her B.S. in chemistry from The Ohio State University and her Ph.D. in chemistry from Harvard University, where she was a National Science Foundation Pre-Doctoral Fellow. She earned her Harvard Ph.D. under the guidance of Professor Dudley Herschbach, the 1986 Nobel Laureate in Chemistry. (http://www.psvf.com/stella-m-sung.asp)

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. ("the Company") is a holding company that operates in the biotechnology space, which includes medical devices and development of proprietary drug compounds. The mission of the Company is to acquire a diversified portfolio of medical technologies with the aim of providing financial and human capital resources, to unlock significant value for the shareholders. The Company's business model entails the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at URL address (www.taurigasciences.com).

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission.



For more information please contact:

Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Tauriga Sciences, Inc.
New York: +1-917-796-9926
Montreal: +1-514-840-3697

SOURCE: Immunovative, Inc.

April 08, 2013 11:40 ET

Immunovative, Inc. Announces That Name Change to Tauriga Sciences Inc., and Symbol Change to "TAUG" Are Effective at Start of Market Trading on Tuesday, April 9, 2013


SAN FRANCISCO, CA--(Marketwired - Apr 8, 2013) - Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) has today announced that its name and trading symbol changes to Tauriga Sciences, Inc. and (OTCQB: TAUG) respectively, will be effective at market open on Tuesday, April 09, 2013 ("tomorrow"). The Company was notified this morning by FINRA that this corporate action ("name and symbol change") was approved and that the name and symbol change will be announced today (04/08/2013) on FINRA's Daily List. The Company's transfer agent (Clear Trust Transfer) is aware of the corporate action and all previous stock certificates will be automatically processed into shares of Tauriga Sciences, Inc.

Tauriga Sciences Inc. CEO Seth M. Shaw stated, "The Company is pleased to have enacted this name and symbol change to better reflect the future direction and nature of the Company. The Company and its management are work diligently to create shareholder by taking advantage of the significant opportunities available to us in life sciences space. Management greatly appreciates the extraordinary level shareholder support that it has received over the previous months and is committed to building a innovative and successful Company in the future."

The Company's new corporate website is currently under development and a press release will be issued to shareholders to notify the public of the upcoming launch date; the new URL address will be www.taurigasciences.com

About Tauriga Sciences, Inc.:

Tauriga Sciences Inc. ("the Company") is a holding company that operates in the biotechnology space, which includes medical devices and development of proprietary drug compounds. The mission of the Company is to acquire a diversified portfolio of medical technologies with the aim of providing financial and human capital resources, to unlock significant value for the shareholders. The Company's business model entails the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at URL address (www.taurigasciences.com).

DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.


Contact Information

Contact:
For more information please contact:

Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Tauriga Sciences, Inc. (Formerly Known as: Immunovative, Inc.)
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sethsms47@aol.com

Zalicuslicious http://taurigasciences.com/

Web Site is being worked on.

Blackcat7717

Hi Zalicuslicious,Big Jewish Holiday (PASSOVER) from March 25,2013 to April 1, 2013. MHB is the one who will update us on ITL not Oceanlow1.

Many people will also be celebrating Easter. Take the next few day off.

I am looking forward to the month of April & May.
Seth Shaw has been working his A** off. for IMUN.

Blackcat7717

VIVA, VIVA, VIVA, SETH SHAW.

BLACKCAT7717

ALL ABOARDDDD! TRAIN WILL BE LEAVING SOON.

BLACKCAT7717

LONG & STRONGER!

BLACKCAT7717

Thank You very much. I am sure everyone on this board will be grateful for your help.

Blackcat7717

Good Post MHB. Lets try to find out if the Bangkok Trials
will begin in April?

Thanks
Blackcat7717

Good Post Doc21. Can you find out if the Bangkok Trial
will begin in April?

Blackcat7717

Zalicuslicious, I have been a buyer all morning. The sellers that are out today are the ones that want to own ITL direct without any SEC oversight(non-reporting company). Owning 150,000 shares of IMUN at $.06 is equal to owning 9,000 shares of ITL at $1.00. IMUN is a great deal more liquid for us to buy & sell. IMUN owns 9% of ITL. We would get the benefit of owning 2 stocks at the same time. I believe you would be carrying less risk to own IMUN instead of buying ITL direct. IMUN will soon merge with another company. Then we will have a shareholder interest in 2 companies at the same time with less risk. Remember, IMUN is a reporting company with SEC oversight.

Blackcat7717